US · Healthcare · Drug Manufacturers - General
EPS came in at 3.60 against a street estimate of 3.04 — a beat of 18.4%.
Analysts rate Biogen Inc a buy (17 buy, 20 hold, 0 sell out of 37) with an average price target of $237.19.
CONFIDENT Q2 beat expectations with 4% pharma revenue growth and strong pipeline momentum. Growth portfolio ($1B+) now exceeds legacy MS. Five Phase III registrational readouts imminent across lupus, AMR, and Dravet syndrome through 2027. Q2 2026 U.S. remains primary Apellis integration market and Alzheimer's growth driver; international markets leading SPINRAZA high-dose adoption; ex-U.S. critical for rare disease expansion. Analysts pressed on SPINRAZA momentum (delivered strong conversion data), lupus trial design rigor (Priya emphasized heterogeneity controls), and felzartamab AMR powering (robust design confirmed). Management signaled discipline: deprioritized crowded BTK RRMS, took pause on Der Nursing despite Phase II signal. 2026-07-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.81% |
| PRIMECAP Management Company | 10.26% |
| FMR Inc | 8.67% |
| Vanguard Capital Management, LLC | 6.45% |
| State Street Corp | 4.85% |
| Vanguard Portfolio Management, LLC | 4.42% |
| Geode Capital Management, LLC | 2.94% |
| Wellington Management Company LLP | 2.11% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 BIOGEN INC. - Q2 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (6 months): $5,213.8 million vs. $5,076.5 million in prior year (2.7% incre | 2026-07-29 |
| Results announced · Q3 2026 BIOGEN Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue $2.7 billion, up 3% year-over-year (2% at constant currency) • GAAP diluted EPS $0. | 2026-07-29 |
| Results announced · Q3 2026 BIOGEN INC. (BIIB) – FORM 8-K SUMMARY HEADLINE NUMBERS • Q2 2026: Acquired in-process R&D, upfront and milestone expenses of approximately $164 mill | 2026-07-01 |
| Shareholder vote results · Q2 2026 BIOGEN INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 9, 2026 • Total votes cast across all proposals: approximatel | 2026-06-10 |
| Material agreement · Q2 2026 BIOGEN INC. - 8-K FILING SUMMARY (May 14, 2026) HEADLINE NUMBERS • Acquisition price: Approximately $5.3 billion in aggregate consideration (excludi | 2026-05-14 |
| Quarterly report · Q1 2026 BIOGEN INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Q1 2026 Total Revenue: $2,477.8 million vs. Q1 2025: $2,431.0 million (+1.9% year-over-year) • | 2026-04-29 |
| Proxy statement · Q2 2026 BIOGEN INC. — 2026 PROXY STATEMENT SUMMARY CEO COMPENSATION & CHANGE • CEO (Chris Viehbacher) total compensation for 2025 not numerically stated in | 2026-04-28 |
| Annual report FY2025 BIOGEN INC. – 2025 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Market capitalization of common stock held by non-affiliates: $18.4 billion (as of June | 2026-02-06 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquired in-process R&D expenses from research and development acquisition Biogen announced significant one-time charges related to research and development acquisitions and licensing deals. In Q2 2026, the company expects a $164 million pre-tax charge that will re | 2026-07-01 |
| Merger with Apellis Pharmaceuticals consummated Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026. This 8-K filing announces the merger's completion and provides references to financial documents. Key details: Bi | 2026-05-14 |
| Collaboration and license agreements with upfront and milestone payments Biogen announced that its Q1 2026 financial results will include a one-time charge of approximately $34 million ($0.19 per diluted share) related to acquired in-process research and developm | 2026-04-06 |
| Entered into Agreement and Plan of Merger with Apellis Pharmaceuticals Biogen Inc. announced on March 31, 2026, that it is acquiring Apellis Pharmaceuticals, Inc. through a tender offer and merger. Under the agreement, Biogen will pay Apellis shareholders $41.0 | 2026-03-31 |
| Acquired in-process R&D and upfront milestone expenses of $222 million Biogen announced that its fourth quarter 2025 results will include a $222 million pre-tax charge for acquired in-process research and development (IPR&D), upfront payments, and milestone exp | 2026-01-14 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biogen Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.